In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Validity of activity data collected by mobile Apple devices - Testing a new telemedical care concept for patients after hospitalization for heart failure.

Session Digital health in clinical practice

Speaker Stefanie Maria Werhahn

Event : ESC Congress 2018

  • Topic : e-cardiology / digital health, public health, health economics, research methodology
  • Sub-topic : Digital Health
  • Session type : Rapid Fire Abstracts

Authors : SM Werhahn (Göttingen,DE), H Dathe (Göttingen,DE), T Rottmann (Göttingen,DE), T Franke (Göttingen,DE), C Wheeler (London,GB), M Fili (London,GB), G Hasenfuss (Göttingen,DE), T Seidler (Göttingen,DE)

S.M. Werhahn1 , H. Dathe2 , T. Rottmann2 , T. Franke2 , C. Wheeler3 , M. Fili3 , G. Hasenfuss1 , T. Seidler1 , 1Universitätsmedizin Göttingen, Kardiologie - Göttingen - Germany , 2Universitätsmedizin Göttingen, Institut für Medizinische Informatik - Göttingen - Germany , 3Medopad Ltd - London - United Kingdom ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 225

Background: Due to the widespread use of mobile devices like smart watches and smart phones, “mobile health”- (mhealth-) applications open up promising possibilities of biomedical data collection and telemedical care concepts. However, sufficient evidence on data quality and the clinical benefit of these mhealth-concepts is often missing.

Purpose: This abstracts presents the results of a pilot study testing a new telemedical care concept designed for patients with newly diagnosed heart failure.The trial analysed patient acceptance and feasibility of this specific mHealth approach. To evaluate the usability of activity data collected by mobile devices, a comparison of the device-related data with those of standardized clinical examinations was performed.

Materials and methods: The tested telemonitoring platform was designed for the combination of iPhone and Apple Watch. It comprises an active part for the patient that consists of daily input of relevant clinical data (blood pressure, bodyweight, symptoms, drug intake) into the iPhone App. The App has access to health-related data as heart frequency and daily steps that are measured passively during the day. All biomedical data are transferred continuously to the doctor in charge using encrypted connections.

In the present feasibility trial, the mHealth concept was tested over a period of two months in ten study participants who were hospitalized for newly diagnosed heart failure (LVEF ≤40%, NYHA ≥ II). For the duration of study, patients were provided an iPhone 6 SE as well as a first generation Apple Watch. At study inclusion as well as after one and two months, participants underwent the following examinations: transthoracic echocardiography, NTproBNP i.s., spiroergometry, questionnaires for heart failure and anxiety, 4 days Holter ECG, 6 minute walk test (6 MWT). A device-based 6 MWT was opposed to the standard 6 MWT.

Results: In questionnaires, the app received good values for usability and patient acceptance. Over the study period, the weekly average of daily steps showed a significant increase (2880 steps/day ± 2318 at study inclusion and 6095 steps/day ± 4158 at the end of study; p<0.0001) that correlated with an improvement of conventional parameters (LVEF in TTE, NT-proBNP, spiroergometry). The walking distance of the standard 6 MWT (578 m ± 166) didn't differ significantly from that of the device-related 6 MWT (vs. 520 m ± 111), but showed a strong correlation (r=0,929; p<0,001). A head-to-head comparison of heart frequency data measured by the Apple Watch with those of Holter ECGs will be presented.

Conclusion: Our pilot study shows that the developed mhealth- concept is suitable to telemonitor patients with heart failure. Device-collected activity data showed a strong correlation with conventional diagnostic parameters. Mhealth- applications may therefore be regarded as promising tools for telemedical care concepts and possible endpoints in clinical heart failure studies.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are